Krystal Biotech (BSP:K1YS34) Cyclically Adjusted Book per Share: R$2.69 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:K1YS34 Krystal Biotech Inc BSP:K1YS34
56 GF Score
Price R$44.80
GF Value R$43.83
! 3 Warning Signs
View Full Analysis

What is Krystal Biotech Cyclically Adjusted Book per Share?

Krystal Biotech BSP:K1YS34 56 Cyclically Adjusted Book per Share is R$2.69 as of Jun. 2026. GuruFocus rates BSP:K1YS34 with a GF Score™ of 56/100 and a GF Value™ of R$43.83. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Krystal Biotech's adjusted book value per share for the three months ended in Jun. 2026 was R$235.312. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$2.69 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-09-12), Krystal Biotech's current stock price is R$44.80. Krystal Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was R$2.69. Krystal Biotech's Cyclically Adjusted PB Ratio of today is 16.65.

During the past 10 years, the highest Cyclically Adjusted PB Ratio of Krystal Biotech was 16.83. The lowest was 14.65. And the median was 15.56.


Krystal Biotech  (BSP:K1YS34) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Krystal Biotech's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=44.80/2.69
=16.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 10 years, the highest Cyclically Adjusted PB Ratio of Krystal Biotech was 16.83. The lowest was 14.65. And the median was 15.56.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Krystal Biotech Cyclically Adjusted Book per Share Related Terms


Krystal Biotech Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Krystal Biotech's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krystal Biotech Cyclically Adjusted Book per Share Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Krystal Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 2.69

BSP:K1YS34 vs AXSM, APGE, IONS: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Krystal Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Krystal Biotech Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's Cyclically Adjusted PB Ratio falls into.


BSP:K1YS34
56GF Score
Krystal Biotech Inc BSP:K1YS34
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krystal Biotech Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Krystal Biotech's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=235.312/333.9520*333.9520
=235.312

Current CPI (Jun. 2026) = 333.9520.

Krystal Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.000 241.428 0.000
201612 -0.432 241.432 -0.598
201703 0.000 243.801 0.000
201706 1.288 244.955 1.756
201709 15.360 246.819 20.782
201712 15.816 246.524 21.425
201803 15.075 249.554 20.173
201806 16.488 251.989 21.851
201809 19.569 252.439 25.888
201812 30.473 251.233 40.506
201903 29.113 254.202 38.247
201906 45.119 256.143 58.825
201909 49.422 256.759 64.280
201912 47.992 256.974 62.368
202003 55.798 258.115 72.192
202006 81.714 257.797 105.853
202009 82.676 260.280 106.077
202012 76.224 260.474 97.726
202103 109.294 264.877 137.796
202106 94.782 271.696 116.500
202109 96.910 274.310 117.981
202112 133.157 278.802 159.497
202203 108.331 287.504 125.833
202206 109.982 296.311 123.953
202209 110.291 296.808 124.093
202212 106.323 296.797 119.633
202303 98.851 301.836 109.369
202306 113.316 305.109 124.028
202309 132.414 307.789 143.670
202312 135.113 306.746 147.096
202403 139.514 312.332 149.171
202406 157.385 314.175 167.292
202409 170.589 315.301 180.680
202412 200.523 315.605 212.180
202503 196.195 319.799 204.878
202506 199.510 322.561 206.556
202509 210.545 324.800 216.478
202512 227.924 324.054 234.886
202603 226.816 330.213 229.384
202606 235.312 333.952 235.312

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of R$2.69 mean?
Krystal Biotech (BSP:K1YS34) has a Cyclically Adjusted Book per Share of R$2.69 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Krystal Biotech and its competitors.
Is Krystal Biotech's Cyclically Adjusted Book per Share too high?
Krystal Biotech's current Cyclically Adjusted Book per Share is R$2.69. Overall, Krystal Biotech has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Cyclically Adjusted Book per Share compare to AXSM and APGE?
Krystal Biotech's Cyclically Adjusted Book per Share of R$2.69 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Krystal Biotech and its competitors. Krystal Biotech's current Cyclically Adjusted Book per Share is R$2.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Krystal Biotech (BSP:K1YS34) has a current Cyclically Adjusted Book per Share of R$2.69. The stock's GF Value™ is R$43.83, compared to a current price of R$44.80 — trading 2.2% above its estimated fair value. The current Cyclically Adjusted Book per Share is R$2.69. Krystal Biotech's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Krystal Biotech (BSP:K1YS34), the current Cyclically Adjusted Book per Share is R$2.69 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krystal Biotech (BSP:K1YS34) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of R$44.80 is trading 2.2% above its estimated GF Value™ of R$43.83.

Key valuation signals for BSP:K1YS34:

  • Cyclically Adjusted Book per Share: R$2.69
  • GF Value™: R$43.83 vs. price of R$44.80 (2.2% above fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the BSP:K1YS34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Krystal Biotech Business Description

Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
56GF Score

Get the complete analysis for BSP:K1YS34

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$44.80
Price
R$43.83
GF Value